SAA, ADAMTS13
Diagnostic Test
Serum Amyloid A (SAA) / ADAMTS13 Panel (2-Plex)
Use this test for acute phase inflammatory detection, chronic inflammatory diseases
1-5 Days
Samples collected for immune-related biomarkers are stable for approximately 1 year if kept frozen (-80˚C preferred). Samples that are left at room temperature beyond 30 minutes during sample collection or are stored at 4˚C are not stable and are not acceptable unless they are processed in BD P-100 tubes.
Luminex® 100/200 (Addressable LASER Bead Immunoassay)
Plasma-EDTA, Serum (Reference intervals estimated from plasma-EDTA only - ADAMTS13 levels are higher in serum, so qualitative calls for that analyte may be misleading for serum samples)
Clinical Use
Clinical Associations
SAA is a key factor in the acute phase inflammatory response and its circulating levels rise dramatically (up to 1000-fold) in response to inflammatory stimuli. SAA has cytokine-like properties in inflammation, contributing to the regulation of immune cells and the induction of both pro-inflammatory and anti-inflammatory factors, indicating homeostatic roles for SAA in both the progression and resolution of inflammation. Although SAA is highly expressed in all inflammatory responses, it is a reliable biomarker for autoimmune and rheumatic diseases and is thought to contribute to the pathogenesis of rheumatoid arthritis, familial Mediterranean fever, sarcoidosis and vasculitis.
ADAMTS13 is a liver enzyme (metalloproteinase / zinc protease) that acts to cleave and degrade von Willebrand factor (VWF) (a protein that promotes platelet adhesion to sites of vascular damage). ADAMTS13 also acts as a carrier protein for blood-clotting factor VIII in blood circulation. Abnormalities in ADAMTS13 are associated with disordered clotting (coagulation).